GlassScriptPhysician profile
Carlos Robles
NPI 1992755441
$7,802.29
in general payments reported to CMS, 2019-2025
38 companies · $1,537 in 2025
The $1,537 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,098 · 2020: $322 · 2021: $534 · 2022: $665 · 2023: $2,478 · 2024: $1,169 · 2025: $1,537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,655 · Consulting Fee: $1,200 · Education: $328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,655.39 |
| Consulting Fee | $1,200.00 |
| Education | $327.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pentax of America, INC. | $1,200.00 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $792.67 | 2019-2025 | Enhertu, Calquence |
| Janssen Biotech, INC. | $597.73 | 2019-2025 | Rybrevant |
| Merck Sharp & Dohme LLC | $591.71 | 2019-2025 | Keytruda, Welireg |
| E.R. Squibb & Sons, L.L.C. | $533.12 | 2019-2024 | Opdivo |
| Gilead Sciences, INC. | $452.55 | 2021-2025 | Trodelvy |
| Emd Serono, INC. | $444.69 | 2023-2025 | Bavencio |
| Seagen INC. | $379.51 | 2020-2023 | Tukysa, Padcev |
| Incyte Corporation | $373.26 | 2019-2025 | Monjuvi, Jakafi, Jakafi |
| Eisai INC. | $247.73 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $193.83 | 2019-2024 | |
| Heron Therapeutics, INC. | $180.23 | 2020-2022 | |
| Myriad Genetic Laboratories, INC. | $175.43 | 2022-2025 | Myrisk, Endopredict |
| Celgene Corporation | $173.33 | 2019-2025 | Reblozyl |
| Pharmacosmos Therapeutics INC. | $166.78 | 2023-2025 | Monoferric |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $155.07 | 2019-2023 | Polivy, Lunsumio |
| Daiichi Sankyo INC. | $129.95 | 2020-2025 | Datroway |
| Regeneron Healthcare Solutions, INC. | $125.37 | 2022-2024 | Libtayo |
| Stemline Therapeutics INC. | $118.07 | 2023-2025 | Orserdu |
| Amgen INC. | $103.80 | 2019-2025 | Imdelltra (Amg757), Lumakras |
| Dendreon Pharmaceuticals LLC | $99.66 | 2023-2025 | Provenge |
| Abbvie INC. | $72.07 | 2019-2022 | |
| Pfizer INC. | $70.85 | 2024-2025 | |
| Glaxosmithkline, LLC. | $51.46 | 2025 | Ojjaara |
| Genzyme Corporation | $49.99 | 2019-2020 | |
| Tempus Ai, INC | $46.17 | 2024-2025 | Xt Cdx |
| Jazz Pharmaceuticals INC. | $41.85 | 2020-2025 | |
| Exelixis INC. | $32.23 | 2019-2020 | |
| Medtronic, INC. | $31.59 | 2025 | Synchromedii |
| Takeda Pharmaceuticals U.S.A., INC. | $29.18 | 2025 | Fruzaqla |
| Beigene USA, INC. | $26.52 | 2025 | Tevimbra |
| Beone Medicines USA, INC. | $24.43 | 2025 | Tevimbra |
| Tersera Therapeutics LLC | $24.13 | 2019 | |
| Adaptive Biotechnologies Corporation | $19.49 | 2021 | |
| Verastem, INC. | $13.09 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.73 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $12.11 | 2019 | |
| Clovis Oncology, INC. | $9.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Robles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.